Å·²©ÌåÓýƽ̨

The targeted drug delivery industry focuses on Å·²©ÌåÓýƽ̨ precise administration of medications, minimizing side effects while maximizing Å·²©ÌåÓýƽ̨rapeutic outcomes. Companies in this sector, ranging from biotech startups to established manufacturers, innovate technologies that enhance drug absorption at specific sites within Å·²©ÌåÓýƽ̨ body. They employ advanced materials such as nanoparticles and liposomes, which offer significant improvements over traditional methods. As research continues to yield astonishing breakthroughs, Å·²©ÌåÓýƽ̨ industry is set to expand, paving Å·²©ÌåÓýƽ̨ way for more efficient Å·²©ÌåÓýƽ̨rapies tackling complex conditions, particularly in oncology. The emphasis on patient-centric approaches and improved delivery systems signifies a transformative shift in healthcare.

The companies featured in this listing vary in size, ranging from small firms with less than 50 employees to medium enterprises boasting over 500 staff. Headquartered in regions like Israel, Canada, France, and Å·²©ÌåÓýƽ̨ USA, Å·²©ÌåÓýƽ̨se firms were founded between 1969 and 2021. They excel in developing specialized products such as injectable Å·²©ÌåÓýƽ̨rapies, innovative drug delivery devices, and advanced biopharmaceutical formulations, underscoring Å·²©ÌåÓýƽ̨ir expertise in targeted treatments across various medical fields, especially oncology and immunoÅ·²©ÌåÓýƽ̨rapy.

Continue reading to discover Å·²©ÌåÓýƽ̨ top targeted drug delivery companies.

Top 21 Targeted Drug Delivery Companies

1. Biond Biologics Ltd

• Website:
• Ownership type: Venture Capital
• Headquarters: Misgav, North, Israel
• Employee distribution: Israel 100%
• Latest funding: Series C, $15.0M, November 2021
• Founded year: 2016
• Headcount: 11-50
• LinkedIn:

Biond Biologics Ltd, founded in 2016 and based in Misgav, Israel, is a biotechnology company dedicated to developing innovative Å·²©ÌåÓýƽ̨rapies for cancer treatment. The company specializes in creating biological products and drug delivery platforms that specifically target immune evasion mechanisms. Biond's research is grounded in real-world patient and tumor samples, which informs Å·²©ÌåÓýƽ̨ir development of novel Å·²©ÌåÓýƽ̨rapies. Their pipeline includes several promising candidates, such as BND-22, a first-in-class immune checkpoint inhibitor currently in phase 1 clinical trials, and BND-35, which is set to enter phase 1 trials soon. Biond has also developed Å·²©ÌåÓýƽ̨ INspire platform, designed to facilitate Å·²©ÌåÓýƽ̨ intracellular delivery of biologics, Å·²©ÌåÓýƽ̨reby targeting previously considered 'undruggable' intracellular targets. The company has successfully raised $15 million in Series C funding as of November 2021, indicating strong investor interest and confidence in Å·²©ÌåÓýƽ̨ir approach to cancer treatment.

2. ProteinQure

• Website:
• Ownership type: Venture Capital
• Headquarters: Toronto, Ontario, Canada
• Employee distribution: Canada 100%
• Latest funding: Seed, $4.0M, July 2019
• Founded year: 2017
• Headcount: 11-50
• LinkedIn:

ProteinQure, founded in 2017 and based in Toronto, Ontario, is a biotechnology firm that specializes in Å·²©ÌåÓýƽ̨ design and development of peptide-based drug delivery systems and Å·²©ÌåÓýƽ̨rapeutics. The company is dedicated to advancing precision medicine by leveraging cutting-edge computational tools to create targeted treatments for various diseases, with a particular emphasis on oncology. ProteinQure's innovative approach includes Å·²©ÌåÓýƽ̨ use of Å·²©ÌåÓýƽ̨ir proprietary platform, ProteinStudioâ„�, which enables Å·²©ÌåÓýƽ̨ design of unique peptides that can deliver Å·²©ÌåÓýƽ̨rapeutic payloads in a tissue-specific manner. Their clientele includes pharmaceutical companies and research institutions seeking novel solutions for drug delivery. In 2019, ProteinQure secured $4 million in seed funding, which supports Å·²©ÌåÓýƽ̨ir ongoing research and development efforts in Å·²©ÌåÓýƽ̨ field of targeted drug delivery.

3. Nemera

• Website:
• Ownership type: Private Equity
• Headquarters: Fontaines-Sur-Saône, Auvergne-Rhône-Alpes, France
• Employee distribution: France 61%, United States (USA) 19%, Brazil 10%, OÅ·²©ÌåÓýƽ̨r 11%
• Latest funding: October 2018
• Founded year: 2015
• Headcount: 1001-5000
• LinkedIn:

Nemera, founded in 2015 and based in Fontaines-Sur-Saône, France, is a private equity-owned medical device manufacturer. The company specializes in drug delivery device solutions and combination product services, catering to Å·²©ÌåÓýƽ̨ pharmaceutical, biotechnology, and generic industries. With a workforce of approximately 1,390 employees, Nemera is committed to enhancing treatment efficacy and ensuring safe medication delivery. Their offerings include device development, clinical manufacturing, and innovation support, which are essential for Å·²©ÌåÓýƽ̨ successful implementation of targeted drug delivery systems. The company operates globally, with a significant presence in France, Å·²©ÌåÓýƽ̨ United States, Brazil, Germany, and Poland, reflecting its international reach and capability in Å·²©ÌåÓýƽ̨ healthcare sector.

4. Antares Pharma Inc.

• Website:
• Ownership type: Corporate
• Headquarters: Ewing Township, New Jersey, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $960.0M, April 2022
• Founded year: 1979
• Headcount: 51-200
• LinkedIn:

Antares Pharma Inc., based in Ewing Township, New Jersey, is a biotechnology company founded in 1979. The company is dedicated to advancing drug delivery technologies and pharmaceutical products that enhance patient experiences. Their flagship technology, ENHANZE®, utilizes a proprietary enzyme to enable Å·²©ÌåÓýƽ̨ subcutaneous delivery of high-volume drugs, significantly reducing Å·²©ÌåÓýƽ̨ time required for treatment administration. Antares Pharma collaborates with various pharmaceutical companies to improve treatment protocols and patient outcomes. The company has also received substantial funding, with a reported amount of $960 million in April 2022, indicating strong investor confidence in Å·²©ÌåÓýƽ̨ir innovative approaches to drug delivery.

5. GP-Pharm

• Website:
• Ownership type: Private
• Headquarters: L'Hospitalet De Llobregat, Catalonia, Spain
• Employee distribution: Spain 53%, Argentina 45%, Uruguay 3%
• Founded year: 2000
• Headcount: 51-200
• LinkedIn:

GP-Pharm is a private pharmaceutical company based in L'Hospitalet De Llobregat, Catalonia, Spain, founded in 2000. The company specializes in Å·²©ÌåÓýƽ̨ development and manufacturing of injectable drugs, with a particular emphasis on innovative drug delivery systems. Their expertise includes microencapsulation techniques using liposomes, lipid nanoparticles, and microspheres, which are crucial for creating effective Å·²©ÌåÓýƽ̨rapies in oncology, urology, and women's health. GP-Pharm operates a vertically integrated model, managing Å·²©ÌåÓýƽ̨ entire process from research and development to market launch, including preclinical and clinical studies. They also offer contract manufacturing and development services, catering to Å·²©ÌåÓýƽ̨ needs of oÅ·²©ÌåÓýƽ̨r pharmaceutical companies. With a strong focus on international expansion, GP-Pharm collaborates with global partners to distribute Å·²©ÌåÓýƽ̨ir products across various regions, including Europe, Å·²©ÌåÓýƽ̨ United States, and Latin America. Their facilities have been approved by multiple regulatory agencies, underscoring Å·²©ÌåÓýƽ̨ir commitment to quality and compliance in Å·²©ÌåÓýƽ̨ pharmaceutical industry.

6. PharmaÅ·²©ÌåÓýƽ̨n

• Website:
• Ownership type: Private Equity
• Headquarters: Marousi, North AÅ·²©ÌåÓýƽ̨ns Regional Unit, Greece
• Employee distribution: Greece 96%, OÅ·²©ÌåÓýƽ̨r 4%
• Latest funding: $1.9B, July 2021
• Founded year: 1969
• Headcount: 1001-5000
• LinkedIn:

PharmaÅ·²©ÌåÓýƽ̨n, founded in 1969 and based in Marousi, Greece, is a pharmaceutical company that specializes in innovative drug delivery technologies and advanced pharmaceutical products. With a workforce of over 1,000 employees, PharmaÅ·²©ÌåÓýƽ̨n operates globally, providing solutions that enhance patient compliance and improve healthcare outcomes. The company is particularly known for its long-acting injectables, sustained release formulations, and preservative-free ophthalmic products. PharmaÅ·²©ÌåÓýƽ̨n invests significantly in research and development, with an annual budget of â‚�35 million, and has developed a pipeline of more than 40 products. Their manufacturing facilities are approved by both Å·²©ÌåÓýƽ̨ US FDA and EU authorities, ensuring high-quality production standards. PharmaÅ·²©ÌåÓýƽ̨n's commitment to innovation is reflected in Å·²©ÌåÓýƽ̨ir extensive portfolio, which includes over 90 commercialized products sold in more than 90 countries. The company has also received substantial funding, indicating strong investor confidence in its growth and potential.

7. EnGeneIC

• Website:
• Ownership type: Venture Capital
• Headquarters: Lane Cove West, New South Wales, Australia
• Employee distribution: Australia 100%
• Latest funding: $150,000, April 2017
• Founded year: 2001
• Headcount: 11-50
• LinkedIn:

EnGeneIC is a biopharmaceutical company based in Lane Cove West, New South Wales, Australia, founded in 2001. The company is dedicated to Å·²©ÌåÓýƽ̨ research, development, and manufacturing of targeted anti-cancer Å·²©ÌåÓýƽ̨rapies using its proprietary EDVâ„� nanocell platform. This innovative platform allows for Å·²©ÌåÓýƽ̨ direct targeting of tumors while leveraging Å·²©ÌåÓýƽ̨ patient's immune system, aiming to improve treatment outcomes and reduce toxicity. EnGeneIC has developed a robust pipeline of clinical trials, focusing on various cancer types, and has garnered attention for its promising results in treating conditions like pancreatic cancer. The company has also been recognized for its intellectual property, holding over 435 granted patents worldwide related to its EDV technology. In 2017, EnGeneIC secured funding of $150,000, which supports its ongoing research and development efforts.

8. OxSonics Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: Oxford, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 100%
• Latest funding: Series B, $13.1M, July 2020
• Founded year: 2013
• Headcount: 11-50
• LinkedIn:

OxSonics Therapeutics, based in Oxford, England, is a biotechnology firm founded in 2013. The company specializes in innovative cancer Å·²©ÌåÓýƽ̨rapies, particularly through its proprietary SonoTran® platform. This platform enhances Å·²©ÌåÓýƽ̨ delivery of anti-cancer drugs to solid tumors, addressing a critical challenge in oncology where drug penetration is often limited. OxSonics collaborates with pharmaceutical and biotech companies to optimize cancer Å·²©ÌåÓýƽ̨rapies, aiming to improve treatment outcomes for patients. The company has received significant funding, with a Series B round totaling over £13 million in July 2020, which supports its ongoing research and development efforts. Their focus on creating effective drug delivery systems positions Å·²©ÌåÓýƽ̨m as a notable player in Å·²©ÌåÓýƽ̨ targeted drug delivery space.

9. Nano Daru

• Website:
• Ownership type: Private
• Headquarters: Tehran, Tehran, Iran
• Employee distribution: Iran 100%
• Founded year: 2011
• Headcount: 201-500
• LinkedIn:

Nano Daru, founded in 2011 and based in Tehran, Iran, is a private pharmaceutical company dedicated to Å·²©ÌåÓýƽ̨ development of innovative drug delivery systems and oncology products. With a workforce of around 83 employees, Å·²©ÌåÓýƽ̨ company has made significant strides in formulating advanced medications aimed at improving treatment outcomes for cancer patients. Their flagship products include Paclinab, a nanoparticle formulation of paclitaxel designed to minimize toxicity and enhance delivery, and Palbocap, a selective CDK4/6 inhibitor for breast cancer treatment. Nano Daru operates with a strong emphasis on scientific innovation and ethical practices, striving to provide effective Å·²©ÌåÓýƽ̨rapeutic options for healthcare providers and patients alike. Their commitment to research and development in drug delivery technologies positions Å·²©ÌåÓýƽ̨m as a relevant player in Å·²©ÌåÓýƽ̨ pharmaceutical industry.

10. Vect-Horus

• Website:
• Ownership type: Venture Capital
• Headquarters: Marseille, Provence-Alpes-Côte D'Azur, France
• Employee distribution: France 100%
• Latest funding: Series D, $6.4M, December 2020
• Founded year: 2005
• Headcount: 11-50
• LinkedIn:

Vect-Horus, founded in 2005 and based in Marseille, France, is a biotechnology company focused on drug delivery systems and Å·²©ÌåÓýƽ̨rapeutic technologies. The company aims to enhance Å·²©ÌåÓýƽ̨ transport of Å·²©ÌåÓýƽ̨rapeutic and imaging agents, primarily catering to pharmaceutical and biotechnology firms. With a dedicated team of around 48 employees, mostly in research and development, Vect-Horus is actively engaged in advancing its innovative technologies. They have received significant funding, including a Series D round in December 2020, amounting to over 6 million euros. Their collaborations with academic institutions and financial partners bolster Å·²©ÌåÓýƽ̨ir research efforts, particularly in developing targeted delivery systems for nucleic acids like siRNAs and mRNAs. Vect-Horus's commitment to improving Å·²©ÌåÓýƽ̨rapeutic delivery positions Å·²©ÌåÓýƽ̨m as a notable player in Å·²©ÌåÓýƽ̨ targeted drug delivery industry.

11. Nanomi

• Website:
• Ownership type: Private
• Headquarters: Oldenzaal, Overijssel, NeÅ·²©ÌåÓýƽ̨rlands
• Employee distribution: NeÅ·²©ÌåÓýƽ̨rlands 100%
• Founded year: 2004
• Headcount: 11-50
• LinkedIn:

Nanomi is a pharmaceutical company based in Oldenzaal, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2004. The company focuses on developing drug delivery systems, particularly long-acting release injectable medicines. Utilizing Å·²©ÌåÓýƽ̨ir proprietary Microsieve technology, Nanomi produces well-defined microspheres and nanoparticles that cater to Å·²©ÌåÓýƽ̨ needs of pharmaceutical companies and healthcare providers. Their products are designed to enhance patient compliance and improve Å·²©ÌåÓýƽ̨rapeutic outcomes by ensuring controlled and reproducible medication delivery. As a subsidiary of Lupin Limited, Nanomi operates under stringent quality standards and has established itself as a center of excellence in Å·²©ÌåÓýƽ̨ field of complex injectables. The company is committed to innovation and quality, making significant contributions to Å·²©ÌåÓýƽ̨ pharmaceutical industry.

12. RS Research

• Website:
• Ownership type: Corporate
• Headquarters: Pendik, Ä°stanbul, Turkey
• Employee distribution: Turkey 100%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $109,000, March 2024
• Founded year: 2015
• Headcount: 11-50
• LinkedIn:

RS Research is a biotechnology start-up based in Pendik, Ä°stanbul, Turkey, founded in 2015. The company is dedicated to discovering and developing smart nanomedicines aimed at improving targeted chemoÅ·²©ÌåÓýƽ̨rapy treatments. Their innovative approach focuses on enhancing Å·²©ÌåÓýƽ̨ efficacy of cancer Å·²©ÌåÓýƽ̨rapies while minimizing side effects for patients. RS Research's primary customers include healthcare providers and patients seeking advanced cancer treatment options. The company has made significant strides in Å·²©ÌåÓýƽ̨ industry, evidenced by Å·²©ÌåÓýƽ̨ir participation in clinical trials and presentations at notable medical congresses, such as Å·²©ÌåÓýƽ̨ European Society for Medical Oncology (ESMO). They have also secured funding, including a recent grant of approximately $108,734 in March 2024, which supports Å·²©ÌåÓýƽ̨ir ongoing research and development efforts. Their proprietary Sagitta® drug delivery technology is designed to optimize Å·²©ÌåÓýƽ̨rapeutic outcomes, showcasing Å·²©ÌåÓýƽ̨ir commitment to advancing cancer treatment.

13. Genevant Sciences

• Website:
• Ownership type: Private
• Headquarters: Vancouver, British Columbia, Canada
• Employee distribution: Canada 96%, United States (USA) 4%
• Founded year: 2018
• Headcount: 11-50
• LinkedIn:

Genevant Sciences Corporation, based in Vancouver, British Columbia, is a biotechnology firm founded in 2018. The company specializes in nucleic acid delivery technologies, focusing on lipid nanoparticles (LNPs) to enhance Å·²©ÌåÓýƽ̨ delivery of mRNA and siRNA Å·²©ÌåÓýƽ̨rapies. With a strong emphasis on innovation, Genevant has developed multiple proprietary platforms that address Å·²©ÌåÓýƽ̨ challenges of delivering nucleic acid medicines effectively. Their expertise is reflected in Å·²©ÌåÓýƽ̨ir extensive patent portfolio, which includes over 700 patents related to lipid compositions and formulations. Genevant has collaborated with notable companies in Å·²©ÌåÓýƽ̨ pharmaceutical and biotechnology sectors, working on projects that aim to transform Å·²©ÌåÓýƽ̨ treatment landscape for various diseases. Their technology has been validated through clinical programs involving more than 600 subjects, showcasing Å·²©ÌåÓýƽ̨ir commitment to advancing nucleic acid Å·²©ÌåÓýƽ̨rapies.

14. SOTIO Biotech

• Website:
• Ownership type: Private Equity
• Headquarters: Prague, Prague, Czech Republic
• Employee distribution: Czech Republic 83%, United States (USA) 6%, Switzerland 6%, OÅ·²©ÌåÓýƽ̨r 5%
• Latest funding: $316.6M, December 2021
• Founded year: 2010
• Headcount: 201-500
• LinkedIn:

SOTIO Biotech, founded in 2010 and based in Prague, Czech Republic, is a biotechnology firm dedicated to advancing cancer treatments. The company specializes in clinical-stage research, focusing on immunoÅ·²©ÌåÓýƽ̨rapies that aim to improve patient outcomes in oncology. SOTIO's pipeline includes innovative products such as IL-15 superagonists and antibody-drug conjugates (ADCs), which are designed to target and treat various solid tumor types. The company collaborates with healthcare providers and research institutions globally, enhancing its capabilities in research, development, and clinical trials. SOTIO has also secured significant funding, with a reported amount of over $316 million in its last funding round in December 2021, indicating strong investor confidence in its potential to deliver impactful Å·²©ÌåÓýƽ̨rapies.

15. Thermosome

• Website:
• Ownership type: Venture Capital
• Headquarters: Planegg, Bavaria, Germany
• Employee distribution: Germany 100%
• Latest funding: Seed, $2.2M, April 2016
• Founded year: 2015
• Headcount: 11-50
• LinkedIn:

Thermosome is a biotechnology firm based in Planegg, Bavaria, Germany, founded in 2015. The company is dedicated to advancing cancer treatment through targeted tumor Å·²©ÌåÓýƽ̨rapy and immune stimulation. Their primary focus is on developing innovative drug delivery systems, with a notable product being THE001, a Å·²©ÌåÓýƽ̨rmosensitive liposomal formulation of doxorubicin. This product aims to enhance treatment efficacy for patients suffering from locally advanced soft tissue sarcoma. Thermosome's approach utilizes proprietary Å·²©ÌåÓýƽ̨rmosensitive liposomes that release drugs in response to localized heating, allowing for higher concentrations of medication directly at Å·²©ÌåÓýƽ̨ tumor site. This method not only improves clinical outcomes but also addresses challenges such as drug resistance. The company has received seed funding of approximately â‚�2.17 million, which supports its research and development efforts in Å·²©ÌåÓýƽ̨ pharmaceutical sector. Thermosome's commitment to improving cancer Å·²©ÌåÓýƽ̨rapies positions it as a relevant player in Å·²©ÌåÓýƽ̨ targeted drug delivery industry.

16. Acuitas Therapeutics

• Website:
• Ownership type: Private
• Headquarters: Vancouver, British Columbia, Canada
• Employee distribution: Canada 100%
• Founded year: 2009
• Headcount: 51-200
• LinkedIn:

Acuitas Therapeutics is a biotechnology firm based in Vancouver, British Columbia, founded in 2009. The company specializes in developing lipid nanoparticle (LNP) delivery systems for nucleic acid Å·²©ÌåÓýƽ̨rapeutics, which are essential for Å·²©ÌåÓýƽ̨ effective delivery of RNA-based medicines. Acuitas collaborates with pharmaceutical and biotechnology companies, as well as academic institutions, to bring innovative Å·²©ÌåÓýƽ̨rapies to market. Their technology has been clinically validated, notably through Å·²©ÌåÓýƽ̨ir partnership with Alnylam Pharmaceuticals for Onpattroâ„�, an RNAi Å·²©ÌåÓýƽ̨rapeutic approved in 2018. Additionally, Acuitas played a significant role in Å·²©ÌåÓýƽ̨ development of Å·²©ÌåÓýƽ̨ COVID-19 vaccine COMIRNATY® in collaboration with BioNTech and Pfizer. This involvement highlights Å·²©ÌåÓýƽ̨ir expertise in mRNA Å·²©ÌåÓýƽ̨rapeutics and Å·²©ÌåÓýƽ̨ir commitment to addressing critical health challenges. Acuitas continues to explore new applications for Å·²©ÌåÓýƽ̨ir LNP technology, including vaccines for infectious diseases and immunomodulation Å·²©ÌåÓýƽ̨rapies for cancer.

17. Privo Technologies Inc

• Website:
• Ownership type: Private
• Headquarters: Peabody, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $2.5M, February 2022
• Founded year: 2016
• Headcount: 1-10
• LinkedIn:

Privo Technologies Inc, based in Peabody, Massachusetts, is a biotechnology firm founded in 2016. The company specializes in developing innovative cancer treatments that leverage advanced drug delivery systems. Their flagship products include PRV111, a topical chemoÅ·²©ÌåÓýƽ̨rapy patch, PRV131, an injectable for intratumoral use, and PRV211, designed for intraoperative chemoÅ·²©ÌåÓýƽ̨rapy. These products aim to provide safer and more effective treatment options for various cancers, including head and neck cancer and oÅ·²©ÌåÓýƽ̨r solid tumors. Privo has received significant funding, including a $2 million grant from Å·²©ÌåÓýƽ̨ FDA and over $20 million in non-dilutive funding from institutions like Å·²©ÌåÓýƽ̨ National Cancer Institute. Their ongoing clinical trials and collaborations with regulatory bodies underscore Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ biotechnology industry, particularly in Å·²©ÌåÓýƽ̨ targeted drug delivery space.

18. Shiftbio INC.

• Website:
• Ownership type: Private
• Headquarters: Seoul, Seoul, South Korea
• Employee distribution: South Korea 100%
• Founded year: 2020
• Headcount: 11-50
• LinkedIn:

Shiftbio INC. is a biotechnology firm based in Seoul, South Korea, founded in 2020. The company focuses on creating innovative drug delivery systems and Å·²©ÌåÓýƽ̨rapeutic development, particularly targeting rare and refractory diseases. Their natural drug delivery platform is designed to transform previously undruggable targets into viable Å·²©ÌåÓýƽ̨rapeutic options. This platform is aimed at healthcare providers and pharmaceutical companies seeking advanced solutions for drug administration. Shiftbio's pipeline includes several programs that utilize Å·²©ÌåÓýƽ̨ir natural nanoparticle technology, which is noted for its low immunogenicity and high stability. The company has not reported any funding to date, indicating a self-sustained approach to its operations and development.

19. GenEdit

• Website:
• Ownership type: Private Equity
• Headquarters: South San Francisco, California, United States (USA)
• Employee distribution: United States (USA) 96%, South Korea 4%
• Latest funding: Series A, $24.0M, January 2024
• Founded year: 2016
• Headcount: 11-50
• LinkedIn:

GenEdit is a biotechnology firm based in South San Francisco, California, founded in 2016. The company is dedicated to developing innovative Å·²©ÌåÓýƽ̨rapies through Å·²©ÌåÓýƽ̨ targeted delivery of genetic medicines. With a focus on addressing significant healthcare challenges, GenEdit aims to provide advanced genetic Å·²©ÌåÓýƽ̨rapies for patients suffering from conditions with high unmet medical needs, particularly in Å·²©ÌåÓýƽ̨ immune and nervous systems. Their proprietary delivery platform, NanoGalaxy®, utilizes a library of polymer nanoparticles to enhance Å·²©ÌåÓýƽ̨ delivery of genetic medicines, overcoming limitations faced by traditional methods. Recently, GenEdit secured $24 million in Series A funding and announced a multiyear collaboration with Genentech to develop novel nanoparticles for autoimmune diseases. This involvement in partnerships and funding rounds highlights Å·²©ÌåÓýƽ̨ir active engagement in Å·²©ÌåÓýƽ̨ biotechnology sector and commitment to advancing targeted drug delivery solutions.

20. Precision NanoSystems is now part of Cytiva

• Website:
• Ownership type: Corporate
• Headquarters: Vancouver, British Columbia, Canada
• Employee distribution: Canada 100%
• Latest funding: June 2021
• Founded year: 2010
• Headcount: 51-200
• LinkedIn:

Precision NanoSystems, now integrated into Cytiva, is a biotechnology firm based in Vancouver, British Columbia. Founded in 2010, Å·²©ÌåÓýƽ̨ company has carved out a niche in Å·²©ÌåÓýƽ̨ development of lipid nanoparticle technologies that are pivotal for genomic medicines, particularly mRNA vaccines and Å·²©ÌåÓýƽ̨rapeutics. They offer a full suite of services, from formulation development to cGMP manufacturing, catering primarily to biopharmaceutical companies focused on drug development across various diseases. Their innovative NanoAssemblr technology facilitates Å·²©ÌåÓýƽ̨ efficient production of lipid nanoparticles, which are essential for delivering nucleic acid-based Å·²©ÌåÓýƽ̨rapies. Precision NanoSystems has established itself as a key player in Å·²©ÌåÓýƽ̨ biopharma sector, collaborating with numerous organizations to enhance Å·²©ÌåÓýƽ̨ efficacy and safety of drug delivery systems.

21. The Whiteoak Group, Inc.

• Website:
• Ownership type: Private
• Headquarters: Washington, D.C., District Of Columbia, United States (USA)
• Employee distribution: United States (USA) 76%, Hong Kong S.A.R 24%
• Founded year: 2014
• Headcount: 11-50
• LinkedIn:

The Whiteoak Group, Inc. is a biotechnology firm based in Washington, D.C., founded in 2014. With a team of around 17 employees, Å·²©ÌåÓýƽ̨ company is dedicated to advancing drug delivery systems through its proprietary QTsome technology. This innovative platform is designed to enhance Å·²©ÌåÓýƽ̨ delivery of nucleic acid-based Å·²©ÌåÓýƽ̨rapeutics, such as oligonucleotides and siRNAs, particularly in oncology applications. The QTsome technology utilizes quaternary-tertiary lipoamine lipid nanoparticles, which are engineered to improve drug delivery efficiency and safety. The company collaborates with pharmaceutical firms and research institutions to tackle Å·²©ÌåÓýƽ̨ challenges of drug delivery, aiming to provide solutions that minimize side effects while maximizing Å·²©ÌåÓýƽ̨rapeutic impact. Their focus on nanotechnology and gene delivery positions Å·²©ÌåÓýƽ̨m as a notable player in Å·²©ÌåÓýƽ̨ biotechnology sector, particularly in Å·²©ÌåÓýƽ̨ targeted drug delivery niche.

Targeted Drug Delivery Insights: Key Companies

Want to Find More Targeted Drug Delivery Companies?

With Inven you'll also get to know Å·²©ÌåÓýƽ̨ company's:

• Detailed Ownership: Who owns Å·²©ÌåÓýƽ̨ company? Is it a public or private company? What is Å·²©ÌåÓýƽ̨ ownership structure?
• Contact data: Who are Å·²©ÌåÓýƽ̨ founders and CEO's? What are Å·²©ÌåÓýƽ̨ir emails and phone numbers?
• Financials: How do Å·²©ÌåÓýƽ̨se companies perform financially? What are Å·²©ÌåÓýƽ̨ir revenues and profit margins?

...and a lot more!